Two injections of Sichuan Creed Pharmaceuticals continue to enter administrative approval

Recently, the Sodium Valproate Injection and Micuronium Chloride Injection, which were reported for production by Sichuan Creed Pharmaceuticals under the new registration classification, have entered the administrative examination and approval stage.

Micuronium chloride is a benzyl isoquinoline compound.

At present, only GlaxoSmithKline’s Micuronium Chloride injection is on sale in China.

Production status of new classification of micuronium injection

Source: Mi Nei Net Consistency Evaluation Database

According to data from Minaiwang, two companies, Guangdong Jiabo Pharmaceutical and Sichuan Creed Pharmaceuticals, have submitted applications for the listing of micuronium chloride injections under the new classification.

Sodium valproate is a nitrogen-free broad-spectrum antiepileptic drug that can competitively inhibit Y-aminobutyric acid transaminase, and is effective for various types of minor seizures, myogenic epilepsy, localized grand mal seizures, grand mal seizures and mixed epilepsy.

According to data from Menet.

New classification of valproate injection

Source: Meinenet MED2.

At present, many companies have submitted applications for the listing of sodium valproate injection with imitation of three categories.

Source: Minet database

Note: The statistics are as of March 25.